An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between Roivant Sciences and Pfizer met high expectations for a Phase 2 clinical trial data released Wednesday.
In a clinical study of 245 volunteers, the drug, called RVT-3101, helped 32% of trial participants with ulcerative colitis go into remission, compared to 12% in the placebo group. The drug also performed well at the dose Roivant and Pfizer plan to use in Phase 3 testing.
The treatment works by targeting a protein called TL1A that’s linked to inflammation and tissue scarring. It’s the same strategy that competitor Prometheus Biosciences is employing. That company’s drug performed better than expected in Phase 2 data released last month, helping nearly 27% of trial participants enter remission.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect